In this interview, Mayasari Lim (RoosterBio, MD, USA) discusses the manufacturing of mesenchymal stem cells (MSCs), including the advantages of using commercially available cell banks and the role that extracellular vesicles (EVs) could play in regenerative medicine. Mayasari also explores the challenges of developing an allogeneic regenerative medicine, as well as provides her thoughts on how the availability and application of MSC-based therapies might evolve in the future.
This feature was produced in association with RoosterBio.
Interview questions for Mayasari Lim
00:07 – Please introduce yourself and your company
01:08 – What are the advantages of using commercially available, large-scale cell banks, as opposed to making your own each time you start a new project?
03:02 – What part might EVs play in regenerative medicine?
05:06 – What are the challenges of developing an allogeneic regenerative medicine?
07:26 – Are there any new products/services that we can expect from RoosterBio in the near future, and how do they differ from existing products/services?
10:09 – How could synthetic biology or gene editing improve advanced therapies?
13:52 – How might availability and application of MSC-based therapies evolve in the future?
You might also like: